DNTH - NASDAQ

Dianthus Therapeutics, Inc.

DNTH·NASDAQ

$84.13

+0.88%

HealthcareBiotechnology

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$3.51B

EPS-4.2000

P/E Ratio-20.03

Earnings Date08/06/2026

dnth

Sales/Maturities of Investments

Last Annual Value

312.39M

3-Year CAGR

439%

5-Year CAGR

30%

10-Year CAGR

Adjust for Inflation

Dianthus Therapeutics, Inc. Competitors Analysis of Sales/Maturities of Investments

DNTH · NASDAQ

Company	Sales/Maturities of Investments	CAGR 3Y	CAGR 5Y	CAGR 10Y
Dianthus Therapeutics, Inc. NASDAQ:DNTH	312.39M	59.0%	28.3%	N/A
BridgeBio Oncology Therapeutics Inc. NASDAQ:BBOT	157.86M	N/A	N/A	N/A
AnaptysBio, Inc. NASDAQ:ANAB	424.53M	-1.9%	21.7%	N/A
Nektar Therapeutics NASDAQ:NKTR	284.68M	-24.1%	-24.7%	1.0%
Enliven Therapeutics, Inc. NASDAQ:ELVN	272.90M	31.5%	42.8%	N/A
Sana Biotechnology, Inc. NASDAQ:SANA	46.56M	-48.9%	-30.2%	N/A
Tourmaline Bio, Inc. NASDAQ:TRML	171.84M	103.1%	-1.1%	N/A
Taysha Gene Therapies, Inc. NASDAQ:TSHA	0.00	N/A	N/A	N/A
Atai Beckley Inc. NASDAQ:ATAI	9.05M	-59.8%	N/A	N/A

Dianthus Therapeutics, Inc. Fair Value Envelope

DNTH · NASDAQ

Our analysis suggests that DNTH has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $84.13, this represents a potential HIDDEN relative to our calculated worth for Dianthus Therapeutics, Inc..

HIDDEN

Intrinsic Value

Current Price: $84.13

Related Guides

Blog Categories

Continue your DNTH research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.